Integrating AI in gastrointestinal endoscopy enhances image analysis, reduces diagnostic variability, and improves patient ...
5. The guidance recommends advanced or immunomodulatory therapy after failure of 5-aminosalicylates instead of a "step-up" approach. The recommendations also define moderate to severe disease using a ...
A study published Nov. 14 in Gastroenterology has found a link between inflammatory bowel disease risk and pesticides, along with other environmental pollutants. Manasi Agrawal, MD, a ...
“Despite continued advances, people living with ulcerative colitis and Crohn’s disease ... sustained benefit across symptomatic, clinical, endoscopic, and histologic endpoints for up to ...
Medpage Today on MSN6d
Year in Review: Inflammatory Bowel DiseaseNotable news about inflammatory bowel disease (IBD) in 2024 included a study evaluating loss of response to tumor necrosis ...
MyChesCo on MSN2d
Johnson & Johnson Advances Ulcerative Colitis Treatment with FDA Filing for TREMFYA® Subcutaneous RegimenSPRING HOUSE, PA – Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S ...
[31] Our definition of ulcerative colitis therefore remains based on clinical, endoscopic and histologic criteria that were established over several decades -- a diffuse, continuous and ...
Johnson & Johnson seeks US FDA approval for subcutaneous induction regimen of Tremfya in ulcerative colitis: Spring House, Pennsylvania Monday, November 25, 2024, 11:00 Hrs [IST] ...
The studies also demonstrated endoscopic improvement with the drug ... to include moderately to severely active ulcerative colitis based on findings from QUASAR, an ongoing phase IIb/III induction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback